- Home
- DQ vs KNSA Comparison
DQ vs KNSA Comparison
Compare DQ & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- KNSA
- Stock Information
- Founded
- DQ 2006
- KNSA 2015
- Country
- DQ China
- KNSA United Kingdom
- Employees
- DQ N/A
- KNSA N/A
- Industry
- DQ Semiconductors
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- KNSA Health Care
- Exchange
- DQ Nasdaq
- KNSA Nasdaq
- Market Cap
- DQ 1.4B
- KNSA 1.5B
- IPO Year
- DQ 2010
- KNSA 2018
- Fundamental
- Price
- DQ $13.93
- KNSA $20.21
- Analyst Decision
- DQ Hold
- KNSA Strong Buy
- Analyst Count
- DQ 6
- KNSA 6
- Target Price
- DQ $20.31
- KNSA $37.17
- AVG Volume (30 Days)
- DQ 1.1M
- KNSA 638.0K
- Earning Date
- DQ 04-29-2025
- KNSA 04-29-2025
- Dividend Yield
- DQ N/A
- KNSA N/A
- EPS Growth
- DQ N/A
- KNSA N/A
- EPS
- DQ N/A
- KNSA N/A
- Revenue
- DQ $1,029,080,000.00
- KNSA $423,239,000.00
- Revenue This Year
- DQ N/A
- KNSA $37.21
- Revenue Next Year
- DQ $67.31
- KNSA $2.58
- P/E Ratio
- DQ N/A
- KNSA N/A
- Revenue Growth
- DQ N/A
- KNSA 56.60
- 52 Week Low
- DQ $12.90
- KNSA $16.56
- 52 Week High
- DQ $30.85
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- DQ 32.68
- KNSA 44.56
- Support Level
- DQ $17.70
- KNSA $18.26
- Resistance Level
- DQ $15.02
- KNSA $21.24
- Average True Range (ATR)
- DQ 1.18
- KNSA 1.12
- MACD
- DQ -0.17
- KNSA -0.12
- Stochastic Oscillator
- DQ 18.76
- KNSA 44.43
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.